These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial. Masuda T; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M Vaccine; 2022 May; 40(24):3380-3388. PubMed ID: 35501178 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111 [TBL] [Abstract][Full Text] [Related]
14. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. Keech C; Albert G; Cho I; Robertson A; Reed P; Neal S; Plested JS; Zhu M; Cloney-Clark S; Zhou H; Smith G; Patel N; Frieman MB; Haupt RE; Logue J; McGrath M; Weston S; Piedra PA; Desai C; Callahan K; Lewis M; Price-Abbott P; Formica N; Shinde V; Fries L; Lickliter JD; Griffin P; Wilkinson B; Glenn GM N Engl J Med; 2020 Dec; 383(24):2320-2332. PubMed ID: 32877576 [TBL] [Abstract][Full Text] [Related]
15. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses. Wilkinson B; Patel KS; Smith K; Walker R; Wang C; Greene AM; Smith G; Smith ER; Gurwith M; Chen RT; Vaccine; 2023 Oct; 41(45):6762-6773. PubMed ID: 37739888 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD; Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial. Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632 [TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209 [TBL] [Abstract][Full Text] [Related]
20. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. Áñez G; Dunkle LM; Gay CL; Kotloff KL; Adelglass JM; Essink B; Campbell JD; Cloney-Clark S; Zhu M; Plested JS; Roychoudhury P; Greninger AL; Patel N; McGarry A; Woo W; Cho I; Glenn GM; Dubovsky F; JAMA Netw Open; 2023 Apr; 6(4):e239135. PubMed ID: 37099299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]